Your browser is no longer supported. Please, upgrade your browser.
DTIL Precision BioSciences, Inc. monthly Stock Chart
DTIL [NASD]
Precision BioSciences, Inc.
Index- P/E- EPS (ttm)-2.95 Insider Own0.30% Shs Outstand52.35M Perf Week16.32%
Market Cap631.48M Forward P/E- EPS next Y-2.00 Insider Trans0.00% Shs Float44.88M Perf Month86.12%
Income-106.50M PEG- EPS next Q-0.03 Inst Own49.80% Short Float5.43% Perf Quarter121.10%
Sales22.00M P/S28.70 EPS this Y-135.60% Inst Trans0.77% Short Ratio3.58 Perf Half Y61.74%
Book/sh1.22 P/B10.22 EPS next Y-17.60% ROA-53.10% Target Price17.71 Perf Year-29.83%
Cash/sh2.06 P/C6.07 EPS next 5Y- ROE-105.70% 52W Range4.45 - 23.67 Perf YTD-10.22%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.32% Beta-
Dividend %- Quick Ratio2.90 Sales past 5Y- Gross Margin- 52W Low179.91% ATR0.73
Employees223 Current Ratio2.90 Sales Q/Q51.00% Oper. Margin- RSI (14)82.57 Volatility7.89% 8.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-21.30% Profit Margin- Rel Volume0.96 Prev Close11.93
ShortableYes LT Debt/Eq0.00 EarningsNov 10 BMO Payout- Avg Volume680.79K Price12.47
Recom1.60 SMA2040.08% SMA5068.06% SMA20075.06% Volume654,778 Change4.53%
Jul-27-20Resumed BTIG Research Buy $16
Apr-03-20Downgrade Goldman Buy → Neutral $24 → $7
Mar-05-20Initiated Stifel Buy $21
Feb-25-20Initiated William Blair Outperform
Aug-09-19Initiated BTIG Research Buy $22
Jul-16-19Initiated H.C. Wainwright Buy $21
Apr-22-19Initiated JP Morgan Overweight
Apr-22-19Initiated Jefferies Buy
Apr-22-19Initiated Goldman Buy
Apr-22-19Initiated Barclays Overweight
Nov-24-20 04:05PM  
Nov-20-20 07:00AM  
Nov-13-20 06:12AM  
Nov-10-20 08:45AM  
07:28AM  
07:00AM  
Nov-03-20 12:30PM  
07:00AM  
Oct-15-20 07:00AM  
Oct-14-20 07:00AM  
Sep-28-20 07:00AM  
Sep-21-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 07:21AM  
Sep-09-20 07:00AM  
Sep-02-20 07:00AM  
Aug-19-20 07:00AM  
Aug-13-20 10:35AM  
07:30AM  
07:00AM  
Aug-06-20 12:30PM  
Aug-03-20 07:00AM  
Jul-17-20 10:29AM  
Jul-06-20 07:00AM  
Jul-05-20 04:33PM  
Jun-08-20 07:00AM  
May-26-20 04:01PM  
May-18-20 06:34AM  
May-15-20 08:52AM  
08:15AM  
07:00AM  
May-08-20 12:30PM  
May-07-20 07:00AM  
Apr-28-20 04:45PM  
Apr-27-20 12:31PM  
Apr-15-20 07:00AM  
Apr-07-20 07:00AM  
Apr-02-20 02:54PM  
Mar-12-20 07:26AM  
Mar-11-20 07:24AM  
07:00AM  
Mar-10-20 07:05AM  
Feb-21-20 07:00AM  
Jan-13-20 07:00AM  
Jan-06-20 07:00AM  
Dec-31-19 03:15PM  
07:25AM  
Dec-30-19 03:40PM  
Dec-19-19 06:28PM  
Dec-09-19 04:19PM  
08:42AM  
07:00AM  
Nov-27-19 09:24AM  
Nov-13-19 07:00AM  
Nov-12-19 07:15AM  
Nov-06-19 09:01AM  
Oct-31-19 12:20PM  
Oct-30-19 10:34AM  
06:30AM  
Oct-03-19 10:11AM  
Sep-30-19 07:58AM  
06:30AM  
Sep-26-19 06:30AM  
Sep-23-19 06:30AM  
Sep-17-19 07:10AM  
Sep-16-19 06:30AM  
Sep-04-19 06:30AM  
Aug-28-19 06:30AM  
Aug-14-19 04:30PM  
11:37AM  
Jul-22-19 08:23AM  
Jul-18-19 01:04PM  
06:30AM  
Jul-10-19 03:00PM  
Jul-05-19 01:12PM  
Jun-23-19 08:53PM  
Jun-12-19 06:30AM  
Jun-11-19 06:00AM  
May-29-19 06:30AM  
May-22-19 01:31PM  
May-14-19 06:30AM  
May-09-19 06:30AM  
Apr-29-19 07:05PM  
04:15PM  
Apr-24-19 06:30AM  
Apr-17-19 05:30AM  
Apr-04-19 01:55PM  
Apr-01-19 04:05PM  
Mar-29-19 03:05PM  
Mar-27-19 05:50PM  
04:23PM  
Mar-24-19 05:16PM  
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANSARI ABIDChief Financial OfficerJun 15Option Exercise1.208,78310,540144,401Jun 17 04:00 PM
ANSARI ABIDChief Financial OfficerMay 15Option Exercise1.209,66111,576135,618May 19 07:17 AM
JANTZ DEREKChief Scientific OfficerApr 14Option Exercise1.184,3925,1833,862,738Apr 15 05:26 PM
ANSARI ABIDChief Financial OfficerJan 06Option Exercise1.2020,20024,187123,845Jan 08 08:23 AM
Heery ChristopherChief Medical OfficerDec 19Buy12.082,48530,0212,485Dec 20 04:44 PM